Hepatocellular Carcinoma is the most common type of liver cancer and commonly occurs in patients with underlying liver disorders or infections. The treatment algorithm has traditionally been dominated by targeted therapies, while immunotherapies have emerged as a successful tool more recently. Ample development is underway for immune checkpoint inhibitors across disease stages, both as monotherapy and in combination with targeted therapies, immunotherapies, and locoregional therapies.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Hepatocellular Carcinoma to help guide strategic and tactical commercial development decisions for market participants.